Neurogenic inflammation markers in children with vertebrobasilar arterial system syndrome and recurrent bronchitis

L.S. Ovcharenko, T.V. Slutskaya, T.V. Slutskaya


Background. The study of the neurogenic maintenance characteristics of the recurrent bronchitis (RB) course in children with the vertebrobasilar arterial system syndrome (VBASS) by studying the levels of the final stable metabolites of nitric oxide (FSM NO), substance P and vasoactive intestinal peptide (VIP) will make it possible to establish important elements of the frequent diseases respiratory tract pathogenesis. Materials and methods. Sixty children aged 7 to 11 years old with anamnesis of RB were examined. Two observation groups were formed (30 patients in each): 1) children with RB in the period of somatic well-being and VBASS; 2) children with RB in the period of somatic well-being without VBASS. Results. In children with RB, who have VBASS, as compared to the children without VBASS, we have detected an increase in FSM NO serum levels (by 36.7 %, p < 0.05) (odds ratio (OR) = 6.50, 95% confidence interval (CI) 1.82–23.21, p < 0.05), substance P (by 40.0 %, p < 0.05) (OR = 6.00, 95% CI 1.89–19.04, p < 0.05), a decrease in concentration of VIP (by 26.7 %, p < 0.05) (OR = 3.05, 95% CI 1.05–8.84, p < 0.05) statistically significantly more often. Conclusions. In children with RB and VBASS, during the period of somatic well-being, the focus of the neurogenic inflammatory process takes place, which is accompanied by an autonomous neuronal processes imbalance and predisposition to recurrent bronchopulmonary pathology.


children; bronchitis; substance P; vasoactive intestinal peptide; nitric oxide


Siniscalchi A, Sztajzel R, Malferrari G, Gallelli L. The National Institutes of Health Stroke Scale: Its Role in Patients with Posterior Circulation Stroke. Hospital Topics. 2017:1-3. doi: 10.1080/00185868.2017.1322888.

Neto ACL, Bittar R, Gattas GS, Bor-Seng-Shu E, Oliveira ML, Monsanto RDC, Bittar LF. Pathophysiology and Diagnosis of Vertebrobasilar Insufficiency: A Review of the Literature. Int Arch Otorhinolaryngol. 2017 Jul;21(3):302-7. doi: 10.1055/s-0036-1593448.

Ovcharenko LS, Shamray IV, Vertegel AA. Neuroimmunne mechanisms genesis of recurrent bronchitis in children. Perinatologija i pediatrija.2013;3:118-25. (in Russian).

Wurzel DF, Marchant JM, Yerkovich ST, Upham JW, Petsky HL, Smith-Vaughan H, et al. Protracted bacterial bronchitis in children: natural history and risk factors for bronchiectasis. Chest. 2016;150(5):1101-8. doi: 10.1016/j.chest.2016.06.030.

Dodwell RL, Kendall JB. Respiratory system: applied pharmacology. Anaesthesia & Intensive Care Medicine. 2014;15(11):517-21.

Brooks CR, Dalen CJ, Zacharasiewicz A, Simpson JL, Harper JL, Le Gros G, et al. Absence of airway inflammation in a large proportion of adolescents with asthma. Respirology. 2016;21(3):460-6. doi: 10.1111/resp.12701.

Leal EC, Carvalho E, Tellechea A, Kafanas A, Tecilazich F, Kearney C, et al. Substance P promotes wound healing in diabetes by modulating inflammation and macrophage phenotype. The American journal of pathology. 2015;185(6):1638-48.

Devin JK, Pretorius M, Nian H, Yu C, Billings FT, Brown NJ. Substance P Increases Sympathetic Activity During Combined Angiotensin-Converting Enzyme and Dipeptidyl Peptidase-4 Inhibition Novelty and Significance. Hypertension. 2014;63(5):951-7. doi: 10.1161/HYPERTENSIONAHA.113.02767.

Słoniecka M, Le Roux S, Zhou Q, Danielson P. Substance P enhances keratocyte migration and neutrophil recruitment through interleukin-8. Molecular pharmacology. 2016;89(2):215-25. doi: 10.1097/CCM.0000000000000486.

Muñoz M, Coveñas R. Involvement of substance P and the NK-1 receptor in human pathology. Amino acids. 2014;46(7):17-27. doi: 10.1007/s00726-014-1736-9.

Copyright (c) 2017 CHILD`S HEALTH

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта